https://www.journalhaema.de/lymphome/non-hodgkin-lymphom/morbus-waldenstroem/zanubrutinib-neue-therapieoption-morbus-waldenstroem
Zanubrutinib – Neue Therapieoption bei Morbus Waldenström
M. Waldenström ist schwer zu behandeln. Eine neue Option bietet Zanubrutinib. Details zu dieser Behandlung lesen Sie hier!
zanubrutinibneuebeimorbus
https://www.medinews.it/notizie-newsletter/fda-grants-zanubrutinib-priority-review-for-relapsed-refractory-mantle-cell-lymphoma/
FDA Grants Zanubrutinib Priority Review for Relapsed/Refractory Mantle Cell Lymphoma – Medinews
mantle cell lymphomapriority reviewfdagrantszanubrutinib
https://www.mountsinai.org/clinical-trials/zanubrutinib-lisocabtagene-maraleucel-for-treatment-of-richters-syndrome
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome | Mount Sinai -...
lisocabtagene maraleucelfor themount sinaizanubrutinibtreatment
https://www.gellc.es/investigacion/ensayos-clinicos/estudio-en-llc-llp-sin-tratamiento-previo-zanubrutinib-obinutuzumab/
Estudio en LLC/LLP sin tratamiento previo (zanubrutinib + obinutuzumab) - GELLC
Estudio multicéntrico, no aleatorizado y abierto, para evaluar la eficacia y seguridad de zanubrutinib en combinación con obinutuzumab en pacientes con...
estudiollcllpsintratamiento
https://beonemedaffairs.com/us/publications/real-world-treatment-patterns-and-outcomes-of-zanubrutinib-in-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma-cll-sll/
Real-World Treatment Patterns and Outcomes of Zanubrutinib in Chronic Lymphocytic Leukemia and...
chronic lymphocytic leukemiareal worldtreatmentpatternsoutcomes
https://www.ajmc.com/view/fda-gives-zanubrutinib-approval-for-first-line-r-r-cll-sll
FDA Gives Zanubrutinib Approval for First-line, R/R CLL/SLL | AJMC
Oct 9, 2026 - The broad approval, while expected, will likely signal a milestone in the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
first linefdagiveszanubrutinibapproval